Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Alexander Egeberg; Nana Aviaaja Lippert Rosenø; David Aagaard; Erik Hillo Lørup; Mia-Louise Nielsen; Lea Nymand; Lars Erik Kristensen; Jacob P Thyssen; Simon Francis Thomsen; Rene Lindholm Cordtz; Nikolai Loft; Lone Skov; Lars Erik Bryld; Mads Kirchheiner Rasmussen; Pil Højgaard; Salome Kristensen; Lene Dreyer

doi:10.1016/j.semarthrit.2022.151979

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Aagaard, Erik Hillo Lørup, Mia-Louise Nielsen, Lea Nymand, Lars Erik Kristensen, Jacob P Thyssen, Simon Francis Thomsen, Rene Lindholm Cordtz, Nikolai Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Pil Højgaard, Salome Kristensen, Lene Dreyer

Abstract

OBJECTIVE: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule therapies across various disease entities such as RA, AxSpA, PsA, and psoriasis.

METHODS: We performed a nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, comprising all patients treated with biologics or novel small-molecule therapies for RA, AxSpA, PsA, and psoriasis between January 2015 through May 2021 (DANBIO) and November 2009 to November 2019 (DERMBIO). Drug survival was visualized using Kaplan-Meier curves, and Cox proportional hazards models were used to calculate adjusted Hazard Ratios (HRs) with 95% confidence intervals (CIs) for risk of discontinuing therapy.

FINDINGS: The study comprised a total of 12,089 patients (17,903 treatment series), including 5,104 RA patients (7,867 series), 2,157 AxSpA patients (3,016 series3), 2,551 PsA patients (3,313 series), and 2,577 psoriasis patients (3,707 series). In confounder-adjusted models drug survival in RA was highest for rituximab followed by baricitinib, etanercept and tocilizumab respectively. For AxSpA, drug survival was high for golimumab compared to all other drugs, followed by secukinumab and etanercept and lowest for infliximab. For PsA, tofacitinib and infliximab had the lowest drug survival compared to all other drugs. All other drugs performed almost equally well with a tendency of a somewhat higher drug survival for golimumab, followed by secukinumab and ixekizumab. For psoriasis, drug survival was generally highest for guselkumab.

INTERPRETATION: Differing treatment responses to drugs with various modes of action across RA, AxSpA, PsA and psoriasis emphasize that although these diseases have many overlaps in their pathogenesis, there is a need for an individualized treatment approach that considers the underlying disease, patient profile, and treatment history.

FUNDING: None.

Original language	English
Article number	151979
Journal	Seminars in Arthritis and Rheumatism
Volume	53
ISSN	0049-0172
DOIs	https://doi.org/10.1016/j.semarthrit.2022.151979
Publication status	Published - Apr 2022

Keywords

Antirheumatic Agents/therapeutic use
Arthritis, Psoriatic/drug therapy
Arthritis, Rheumatoid/drug therapy
Axial Spondyloarthritis
Biological Products/therapeutic use
Cohort Studies
Humans
Immunologic Factors/therapeutic use
Prospective Studies
Psoriasis/drug therapy
Registries

Access to Document

10.1016/j.semarthrit.2022.151979

Fingerprint

Dive into the research topics of 'Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries'. Together they form a unique fingerprint.

Cite this

Egeberg, A., Rosenø, N. A. L., Aagaard, D., Lørup, E. H., Nielsen, M.-L., Nymand, L., Kristensen, L. E., Thyssen, J. P., Thomsen, S. F., Cordtz, R. L., Loft, N., Skov, L., Bryld, L. E., Rasmussen, M. K., Højgaard, P., Kristensen, S., & Dreyer, L. (2022). Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Seminars in Arthritis and Rheumatism, 53, Article 151979. https://doi.org/10.1016/j.semarthrit.2022.151979

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. / Egeberg, Alexander; Rosenø, Nana Aviaaja Lippert; Aagaard, David et al.
In: Seminars in Arthritis and Rheumatism, Vol. 53, 151979, 04.2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Egeberg, A, Rosenø, NAL, Aagaard, D, Lørup, EH, Nielsen, M-L, Nymand, L, Kristensen, LE , Thyssen, JP , Thomsen, SF , Cordtz, RL , Loft, N , Skov, L, Bryld, LE, Rasmussen, MK, Højgaard, P, Kristensen, S & Dreyer, L 2022, 'Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries', Seminars in Arthritis and Rheumatism, vol. 53, 151979. https://doi.org/10.1016/j.semarthrit.2022.151979

Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Seminars in Arthritis and Rheumatism. 2022 Apr;53:151979. doi: 10.1016/j.semarthrit.2022.151979

@article{7a4e69ce6de64b79a5752190e27370e4,

title = "Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries",

abstract = "OBJECTIVE: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule therapies across various disease entities such as RA, AxSpA, PsA, and psoriasis.METHODS: We performed a nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, comprising all patients treated with biologics or novel small-molecule therapies for RA, AxSpA, PsA, and psoriasis between January 2015 through May 2021 (DANBIO) and November 2009 to November 2019 (DERMBIO). Drug survival was visualized using Kaplan-Meier curves, and Cox proportional hazards models were used to calculate adjusted Hazard Ratios (HRs) with 95% confidence intervals (CIs) for risk of discontinuing therapy.FINDINGS: The study comprised a total of 12,089 patients (17,903 treatment series), including 5,104 RA patients (7,867 series), 2,157 AxSpA patients (3,016 series3), 2,551 PsA patients (3,313 series), and 2,577 psoriasis patients (3,707 series). In confounder-adjusted models drug survival in RA was highest for rituximab followed by baricitinib, etanercept and tocilizumab respectively. For AxSpA, drug survival was high for golimumab compared to all other drugs, followed by secukinumab and etanercept and lowest for infliximab. For PsA, tofacitinib and infliximab had the lowest drug survival compared to all other drugs. All other drugs performed almost equally well with a tendency of a somewhat higher drug survival for golimumab, followed by secukinumab and ixekizumab. For psoriasis, drug survival was generally highest for guselkumab.INTERPRETATION: Differing treatment responses to drugs with various modes of action across RA, AxSpA, PsA and psoriasis emphasize that although these diseases have many overlaps in their pathogenesis, there is a need for an individualized treatment approach that considers the underlying disease, patient profile, and treatment history.FUNDING: None.",

keywords = "Antirheumatic Agents/therapeutic use, Arthritis, Psoriatic/drug therapy, Arthritis, Rheumatoid/drug therapy, Axial Spondyloarthritis, Biological Products/therapeutic use, Cohort Studies, Humans, Immunologic Factors/therapeutic use, Prospective Studies, Psoriasis/drug therapy, Registries",

author = "Alexander Egeberg and Rosen{\o}, {Nana Aviaaja Lippert} and David Aagaard and L{\o}rup, {Erik Hillo} and Mia-Louise Nielsen and Lea Nymand and Kristensen, {Lars Erik} and Thyssen, {Jacob P} and Thomsen, {Simon Francis} and Cordtz, {Rene Lindholm} and Nikolai Loft and Lone Skov and Bryld, {Lars Erik} and Rasmussen, {Mads Kirchheiner} and Pil H{\o}jgaard and Salome Kristensen and Lene Dreyer",

year = "2022",

month = apr,

doi = "10.1016/j.semarthrit.2022.151979",

language = "English",

volume = "53",

journal = "Seminars in Arthritis and Rheumatism",

issn = "0049-0172",

publisher = "W.B./Saunders Co",

}

TY - JOUR

T1 - Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

AU - Egeberg, Alexander

AU - Rosenø, Nana Aviaaja Lippert

AU - Aagaard, David

AU - Lørup, Erik Hillo

AU - Nielsen, Mia-Louise

AU - Nymand, Lea

AU - Kristensen, Lars Erik

AU - Thyssen, Jacob P

AU - Thomsen, Simon Francis

AU - Cordtz, Rene Lindholm

AU - Loft, Nikolai

AU - Skov, Lone

AU - Bryld, Lars Erik

AU - Rasmussen, Mads Kirchheiner

AU - Højgaard, Pil

AU - Kristensen, Salome

AU - Dreyer, Lene

PY - 2022/4

Y1 - 2022/4

N2 - OBJECTIVE: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule therapies across various disease entities such as RA, AxSpA, PsA, and psoriasis.METHODS: We performed a nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, comprising all patients treated with biologics or novel small-molecule therapies for RA, AxSpA, PsA, and psoriasis between January 2015 through May 2021 (DANBIO) and November 2009 to November 2019 (DERMBIO). Drug survival was visualized using Kaplan-Meier curves, and Cox proportional hazards models were used to calculate adjusted Hazard Ratios (HRs) with 95% confidence intervals (CIs) for risk of discontinuing therapy.FINDINGS: The study comprised a total of 12,089 patients (17,903 treatment series), including 5,104 RA patients (7,867 series), 2,157 AxSpA patients (3,016 series3), 2,551 PsA patients (3,313 series), and 2,577 psoriasis patients (3,707 series). In confounder-adjusted models drug survival in RA was highest for rituximab followed by baricitinib, etanercept and tocilizumab respectively. For AxSpA, drug survival was high for golimumab compared to all other drugs, followed by secukinumab and etanercept and lowest for infliximab. For PsA, tofacitinib and infliximab had the lowest drug survival compared to all other drugs. All other drugs performed almost equally well with a tendency of a somewhat higher drug survival for golimumab, followed by secukinumab and ixekizumab. For psoriasis, drug survival was generally highest for guselkumab.INTERPRETATION: Differing treatment responses to drugs with various modes of action across RA, AxSpA, PsA and psoriasis emphasize that although these diseases have many overlaps in their pathogenesis, there is a need for an individualized treatment approach that considers the underlying disease, patient profile, and treatment history.FUNDING: None.

AB - OBJECTIVE: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule therapies across various disease entities such as RA, AxSpA, PsA, and psoriasis.METHODS: We performed a nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, comprising all patients treated with biologics or novel small-molecule therapies for RA, AxSpA, PsA, and psoriasis between January 2015 through May 2021 (DANBIO) and November 2009 to November 2019 (DERMBIO). Drug survival was visualized using Kaplan-Meier curves, and Cox proportional hazards models were used to calculate adjusted Hazard Ratios (HRs) with 95% confidence intervals (CIs) for risk of discontinuing therapy.FINDINGS: The study comprised a total of 12,089 patients (17,903 treatment series), including 5,104 RA patients (7,867 series), 2,157 AxSpA patients (3,016 series3), 2,551 PsA patients (3,313 series), and 2,577 psoriasis patients (3,707 series). In confounder-adjusted models drug survival in RA was highest for rituximab followed by baricitinib, etanercept and tocilizumab respectively. For AxSpA, drug survival was high for golimumab compared to all other drugs, followed by secukinumab and etanercept and lowest for infliximab. For PsA, tofacitinib and infliximab had the lowest drug survival compared to all other drugs. All other drugs performed almost equally well with a tendency of a somewhat higher drug survival for golimumab, followed by secukinumab and ixekizumab. For psoriasis, drug survival was generally highest for guselkumab.INTERPRETATION: Differing treatment responses to drugs with various modes of action across RA, AxSpA, PsA and psoriasis emphasize that although these diseases have many overlaps in their pathogenesis, there is a need for an individualized treatment approach that considers the underlying disease, patient profile, and treatment history.FUNDING: None.

KW - Antirheumatic Agents/therapeutic use

KW - Arthritis, Psoriatic/drug therapy

KW - Arthritis, Rheumatoid/drug therapy

KW - Axial Spondyloarthritis

KW - Biological Products/therapeutic use

KW - Cohort Studies

KW - Humans

KW - Immunologic Factors/therapeutic use

KW - Prospective Studies

KW - Psoriasis/drug therapy

KW - Registries

UR - http://www.scopus.com/inward/record.url?scp=85124755183&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2022.151979

DO - 10.1016/j.semarthrit.2022.151979

M3 - Journal article

C2 - 35183936

SN - 0049-0172

VL - 53

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

M1 - 151979

ER -

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this